Weight Management Medications for Adolescents: What's Approved

Adolescent obesity affects roughly 1 in 5 young people aged 12–19 in the United States, and the clinical consequences — type 2 diabetes, dyslipidemia, nonalcoholic fatty liver disease, and psychosocial harm — begin well before adulthood. For decades, lifestyle modification was the only recommended approach for obesity medication adolescents could access. That changed substantially between 2020 and 2023, when the FDA expanded approvals for several pharmacotherapies to patients as young as 12, and the American Academy of Pediatrics (AAP) released landmark guidelines endorsing their early, proactive use.

This article reviews every FDA-approved pharmacotherapy currently available for adolescents with obesity, the pivotal trial data behind each, practical dosing guidance, monitoring requirements, and growth-related concerns unique to this population.

---

TL;DR

• Four medications are FDA-approved for weight management in adolescents aged ≥12: semaglutide (Wegovy), liraglutide (Saxenda), orlistat (Xenical), and phentermine-topiramate ER (Qsymia).
• The AAP 2023 guidelines recommend offering pharmacotherapy alongside lifestyle intervention for children ≥12 with obesity (BMI ≥95th percentile).
• Semaglutide 2.4 mg weekly showed the largest effect in the STEP TEENS trial — approximately 16% BMI reduction over 68 weeks.
• All approved agents require concurrent lifestyle modification; none is indicated as monotherapy without behavioral support.
• Growth, bone health, and pubertal development must be monitored throughout treatment.

---

Understanding Adolescent Obesity: Scale and Significance

Pediatric obesity is defined by age- and sex-specific BMI percentiles rather than fixed cutoffs. The CDC growth charts classify overweight as BMI ≥85th to <95th percentile and obesity as ≥95th percentile. Severe obesity — BMI ≥120% of the 95th percentile — now affects approximately 6% of U.S. adolescents.

The health burden is not theoretical. Adolescents with obesity face increased risk of:

• Type 2 diabetes — incidence in youth has risen sharply over the past two decades
• Dyslipidemia and hypertension — precursors to early cardiovascular disease
• Obstructive sleep apnea
• Nonalcoholic steatohepatitis (NASH)
• Depression, anxiety, and weight-based stigma

The AAP's 2023 Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity marked a paradigm shift: it explicitly states that waiting or "watchful waiting" is not a recommended strategy and that intensive health behavior and lifestyle treatment (IHBLT) should begin early, with pharmacotherapy considered for adolescents aged ≥12 with obesity who have not responded adequately to behavioral approaches alone.

---

FDA-Approved Medications: Mechanisms and Comparison

Four pharmacotherapies currently carry FDA approval for weight management in adolescents aged 12 and older. Their mechanisms, approval history, and expected efficacy differ substantially.

Key takeaway: Semaglutide (Wegovy) for teens demonstrated the largest treatment effect of any approved anti-obesity pharmacotherapy in this age group. Liraglutide shows more modest results but has a longer pediatric safety track record. Orlistat's efficacy is limited, and phentermine-topiramate ER, while approved, has less robust adolescent-specific data.

GLP-1 Receptor Agonists

Semaglutide and liraglutide both act as glucagon-like peptide-1 (GLP-1) receptor agonists. They slow gastric emptying, enhance satiety signaling in the hypothalamus, and improve glycemic control. The key difference is pharmacokinetic: semaglutide's longer half-life (~7 days) permits once-weekly dosing compared with liraglutide's daily injection.

Orlistat

Orlistat inhibits gastric and pancreatic lipases, reducing dietary fat absorption by approximately 30%. It does not have central appetite effects. Its use in adolescents is limited by gastrointestinal tolerability and modest efficacy.

Phentermine-Topiramate ER

This fixed-dose combination pairs a sympathomimetic amine (appetite suppressant) with topiramate, an anticonvulsant that independently reduces appetite through uncertain central mechanisms. The FDA approved it for adolescents ≥12 years in 2022, though published adolescent trial data remain more limited compared with the GLP-1 agents.

---

The Evidence: STEP TEENS and Other Pivotal Trials

STEP TEENS (Semaglutide)

The STEP TEENS trial (Weghuber et al., New England Journal of Medicine, 2022) enrolled 201 adolescents aged 12–17 with obesity (BMI ≥95th percentile) or overweight (≥85th percentile) with at least one weight-related comorbidity. All participants received lifestyle intervention.

Key results at 68 weeks:

• Semaglutide group: −16.1% change in BMI from baseline
• Placebo group: +0.6% change in BMI
• Treatment difference: −16.7 percentage points (95% CI, −20.3 to −13.2; p<0.001)
• 73% of semaglutide-treated adolescents achieved ≥5% BMI reduction vs 18% on placebo
• Improvements in waist circumference, HbA1c, lipid parameters, and ALT levels

The safety profile was broadly consistent with adult GLP-1 agonist data. Gastrointestinal adverse events (nausea, vomiting, diarrhea) were the most common treatment-related effects. No new safety signals specific to adolescents emerged, though the study was not powered for rare events.

A critical observation: after treatment discontinuation, participants in an open-label extension experienced weight regain, underscoring that semaglutide adolescent use may need to be long-term, raising questions about duration, cost, and developmental effects over years of treatment.

SCALE Teens (Liraglutide)

The SCALE Teens trial (Kelly et al., New England Journal of Medicine, 2020) randomized 251 adolescents (12–17 years) with obesity to liraglutide 3.0 mg daily or placebo, plus lifestyle therapy, over 56 weeks.

• Liraglutide group: −2.65% estimated BMI reduction (adjusted for placebo)
• 43.3% of liraglutide-treated adolescents achieved ≥5% BMI reduction vs 18.7% on placebo

While the magnitude of effect was smaller than STEP TEENS, the trial confirmed that GLP-1 agonist therapy adds clinically meaningful benefit over lifestyle intervention alone.

Orlistat Adolescent Data

Chanoine et al. (2005) conducted the pivotal 54-week trial in 539 adolescents (12–16 years). BMI decreased by 0.55 kg/m² in the orlistat group vs an increase of 0.31 kg/m² with placebo — a statistically significant but clinically modest difference. Fat-soluble vitamin supplementation was required.

---

Dosing and Practical Use

All approved agents require concurrent lifestyle intervention — structured dietary guidance, increased physical activity, and behavioral counseling. No medication is indicated without this foundation.

Dosing Escalation Schedules

Practical Considerations for Prescribers

• Semaglutide and liraglutide require patient or caregiver training on subcutaneous injection technique. Prefilled pen devices simplify administration, but adolescents and families should receive hands-on instruction.
• Dose escalation for GLP-1 agents exists specifically to mitigate gastrointestinal side effects. Rushing the titration schedule increases nausea and vomiting, which can compromise adherence.
• Orlistat requires concurrent multivitamin supplementation (vitamins A, D, E, K, and beta-carotene) taken at least 2 hours apart from the drug, as it impairs fat-soluble vitamin absorption.
• Phentermine-topiramate ER is available only through a REMS program (Qsymia Certified Pharmacy) and requires pregnancy testing and contraception counseling for females of reproductive potential due to topiramate teratogenicity.
• Treatment response evaluation: The AAP recommends assessing response at 12 weeks. If the adolescent has not achieved a clinically meaningful BMI reduction (generally ≥5% from baseline), clinicians should reconsider the treatment plan — dose optimization, adherence assessment, or medication switch.

---

Side Effects and Monitoring

Common Adverse Effects by Medication Class

GLP-1 receptor agonists (semaglutide, liraglutide):

• Nausea (most common, typically dose-dependent and self-limiting)
• Vomiting, diarrhea, constipation
• Abdominal pain
• Injection site reactions
• Headache, fatigue
• Cholelithiasis (gallstones) — more common with rapid weight loss

Orlistat:

• Oily spotting, flatus with discharge, fecal urgency
• Fat-soluble vitamin deficiency if unsupplemented
• Rare hepatotoxicity (post-marketing reports)

Phentermine-topiramate ER:

• Paresthesia, dysgeusia (taste alteration)
• Insomnia, dry mouth
• Constipation
• Increased heart rate
• Metabolic acidosis (topiramate component)
• Cognitive effects ("word-finding difficulty")
• Teratogenicity — topiramate is associated with oral cleft risk

Recommended Monitoring Schedule

Routine monitoring for adolescents on anti-obesity pharmacotherapy should include:

• Height and weight at every visit — critical for growth velocity assessment
• Tanner staging periodically to ensure normal pubertal progression
• Heart rate and blood pressure — particularly with phentermine-topiramate
• Metabolic panel: fasting glucose, HbA1c, lipid panel, ALT/AST — at baseline and every 3–6 months
• Renal function and bicarbonate — for phentermine-topiramate (metabolic acidosis risk)
• Fat-soluble vitamin levels — for orlistat
• Pregnancy testing — for females on phentermine-topiramate (monthly per REMS)
• Mental health screening — the AAP emphasizes screening for depression and disordered eating behaviors at each visit

---

Contraindications and Drug Interactions

Important for all agents: concurrent use of multiple anti-obesity medications in adolescents is not supported by current evidence and is generally not recommended outside of clinical trials.

---

Special Populations and Growth Considerations

Growth and Pubertal Development

This is the defining concern unique to weight loss medication children and adolescents receive. Unlike adults, adolescents are still gaining height, developing bone mass, and undergoing pubertal maturation. Rapid or excessive weight loss could theoretically:

• Impair linear growth velocity
• Reduce peak bone mineral density
• Delay or disrupt pubertal milestones
• Contribute to nutritional deficiencies during a period of high metabolic demand

In the STEP TEENS trial, semaglutide-treated adolescents continued to grow in height over the 68-week study period, and no clinically significant differences in linear growth were observed compared with placebo. However, long-term data beyond 2 years remain limited, and the AAP emphasizes that monitoring height velocity is essential.

The Endocrine Society recommends that pharmacotherapy for pediatric obesity treatment should be managed by or in consultation with clinicians experienced in pediatric weight management, endocrinology, or adolescent medicine.

Adolescents With Type 2 Diabetes

Semaglutide and liraglutide lower blood glucose in addition to reducing body weight. For adolescents with comorbid type 2 diabetes, GLP-1 agonist therapy may address both conditions simultaneously. However, doses and indications differ: semaglutide for diabetes (Ozempic, max 2.0 mg weekly) is distinct from semaglutide for weight management (Wegovy, 2.4 mg weekly). Prescribers must select the appropriate product and dose.

Adolescents With Eating Disorders

Pharmacotherapy for weight management is contraindicated in the setting of active anorexia nervosa or bulimia nervosa. For adolescents with binge eating disorder and concurrent obesity, individualized assessment by a multidisciplinary team is essential. GLP-1 agonists reduce appetite, which may be beneficial in some patients but harmful in others depending on the specific eating disorder phenotype.

Adolescents With Genetic Obesity Syndromes

Setmelanotide (Imcivree), a melanocortin 4 receptor (MC4R) agonist, is FDA-approved for patients aged ≥6 years with obesity due to confirmed biallelic variants in POMC, PCSK1, or LEPR genes. This agent targets a specific mechanistic pathway and is not indicated for general exogenous obesity.

---

Red Flags — When to Seek Immediate Care

Adolescents (and their caregivers) should be counseled to seek urgent medical evaluation in the following situations:

• Severe, persistent abdominal pain — may indicate pancreatitis (rare but reported with GLP-1 agonists) or cholelithiasis
• Signs of thyroid mass — neck lump, dysphagia, hoarseness (GLP-1 agonists carry a boxed warning regarding thyroid C-cell tumors based on rodent data)
• Suicidal ideation or severe mood changes — any anti-obesity medication; topiramate specifically has CNS effects
• Persistent vomiting or inability to maintain hydration — risk of dehydration, especially during dose escalation of GLP-1 agonists
• Symptoms of metabolic acidosis — hyperventilation, fatigue, anorexia (phentermine-topiramate)
• Signs of allergic reaction — anaphylaxis, angioedema
• Suspected pregnancy — immediate discontinuation of phentermine-topiramate; urgent consultation

---

Frequently Asked Questions

Is Wegovy for teens the same as the adult version?

Yes. Semaglutide 2.4 mg (Wegovy) uses the same formulation and target dose in adolescents aged ≥12 as in adults. The dose escalation schedule is identical. The difference lies in the BMI eligibility criteria — adolescents qualify based on age- and sex-specific BMI percentiles (≥95th percentile) rather than the adult BMI ≥30 kg/m² threshold.

How long does an adolescent need to stay on these medications?

Current evidence suggests that weight regain occurs after discontinuation — this was observed in both the STEP TEENS and SCALE Teens extension data. The AAP 2023 guidelines acknowledge that pharmacotherapy for obesity may need to be long-term, similar to treatment for other chronic diseases such as type 2 diabetes or hypertension. Duration should be individualized based on response, tolerability, growth status, and shared decision-making with the adolescent and family.

Can these medications be used in children under 12?

None of the four medications discussed here is FDA-approved for weight management in children younger than 12. Setmelanotide (Imcivree) is approved from age 6 but only for confirmed monogenic obesity syndromes. Off-label use of anti-obesity medications in children under 12 is not supported by current guidelines.

Do adolescents need to diet while taking these medications?

The term "diet" can be misleading. All approved medications are indicated as adjuncts to lifestyle intervention, which includes nutritionally balanced eating plans, increased physical activity, and behavioral counseling. Restrictive or very-low-calorie diets are generally not recommended for growing adolescents. The goal is sustainable behavior change supported by pharmacotherapy, not short-term caloric restriction.

Will these medications affect my teenager's growth?

Available trial data (up to 68 weeks for semaglutide, 56 weeks for liraglutide) have not demonstrated impaired linear growth. However, very long-term data spanning the entirety of adolescent growth are lacking. Height velocity, Tanner staging, and nutritional status should be monitored at every clinical visit. This is one reason the AAP recommends management by experienced clinicians.

Are GLP-1 agonists covered by insurance for adolescents?

Coverage varies substantially by payer, plan, and region. Many commercial insurers require documentation of failed lifestyle intervention, BMI thresholds, and sometimes prior authorization. Some plans exclude anti-obesity medications entirely. The manufacturer of Wegovy (Novo Nordisk) offers patient assistance programs, though eligibility criteria apply. Families should contact their insurer directly and explore assistance options.

What about semaglutide adolescent use for overweight (not obese) teens?

The FDA approval for Wegovy in adolescents covers those with a BMI at the 95th percentile or greater for age and sex. Adolescents who are overweight (85th to <95th percentile) are not within the approved indication unless they have a BMI ≥95th percentile. Off-label use in this group is not well supported by evidence, and lifestyle intervention remains the primary approach.

Is bariatric surgery still recommended for adolescents?

Yes, for appropriate candidates. The AAP 2023 guidelines recommend that adolescents aged ≥13 with severe obesity (BMI ≥120% of the 95th percentile) be evaluated for metabolic and bariatric surgery. Pharmacotherapy and surgery are not mutually exclusive — they represent different tiers of treatment intensity, and some adolescents may benefit from both sequentially.

---

References

1. Hampl SE, Hassink SG, Skinner AC, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. Pediatrics. 2023;151(2):e2022060640. PMID: 36622115

2. Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022;387(24):2245–2257. PMID: 36546413

3. Kelly AS, Auerbach P, Barrientos-Pérez M, et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020;382(22):2117–2128. PMID: 32233338

4. Chanoine JP, Hampl S, Jensen C, et al. Effect of Orlistat on Weight and Body Composition in Obese Adolescents: A Randomized Controlled Trial. JAMA. 2005;293(23):2873–2883. PMID: 15956632

5. FDA. Highlights of Prescribing Information: Wegovy (semaglutide) injection. 2022. accessdata.fda.gov

6. FDA. Highlights of Prescribing Information: Qsymia (phentermine and topiramate extended-release) capsules. 2022. accessdata.fda.gov

7. Styne DM, Arslanian SA, Connor EL, et al. Pediatric Obesity — Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102(3):709–757. PMID: 28359099

8. NICE. Obesity: identification, assessment and management. Clinical Guideline CG189. 2014 (updated 2023). nice.org.uk/guidance/cg189

9. Skinner AC, Ravanbakht SN, Skelton JA, et al. Prevalence of Obesity and Severe Obesity in US Children, 1999–2016. Pediatrics. 2018;141(3):e20173459. PMID: 29483202

10. CDC. About Child & Teen BMI. Growth Charts. cdc.gov/healthyweight

---

About the Author

Dr. Stanislav Ozarchuk, PharmD, is a clinical pharmacist with 15 years of experience in hospital and ambulatory care settings. He specializes in evidence-based medication review, with particular expertise in metabolic disease pharmacotherapy, pediatric dosing, and patient safety. Dr. Ozarchuk writes for PillsCard.com to provide clinicians and patients with rigorously sourced drug information grounded in current guidelines and primary literature.

---

Medical Disclaimer

This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The information presented reflects published evidence and guideline recommendations available at the time of writing and may not encompass all clinical scenarios. Anti-obesity pharmacotherapy in adolescents should only be initiated and managed by qualified healthcare providers experienced in pediatric weight management. Individual treatment decisions must account for the patient's complete medical history, growth status, and family context. Always consult a licensed healthcare professional before starting, stopping, or changing any medication. PillsCard.com assumes no liability for actions taken based on the content of this article.